Clinical trials: Glial Tumors
Glioblastoma
Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.
The main goal of ORGA-GLIO trial is to establish the feasibility in routine clinical practice of ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and…
- Trial name
- ORGA-GLIO (NCT07029100)
- Testing
- Ex-vivo organoid culture
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Henri Becquerel
Brain and Central Nervous System Tumors
Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002545
- Testing
- carmustine, low-LET photon therapy
- Where
- 260 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Radiation Therapy Oncology Group
Brain and Central Nervous System Tumors
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or…
- Trial name
- NCT00003241
- Testing
- phenylacetate
- Where
- 6 sites in United States
- Sponsor
- Texas Children's Cancer Center
Glioblastoma
Glioblastoma Response Prediction to Apatinib
Anti-angiogenic therapy is an important treatment strategy for recurrent glioblastoma. Our previous study provided evidence for a potential benefit of apatinib, a humanized monoclonal antibody against VEGFR-2, when added to…
- Trial name
- NCT04814329
- Testing
- genetic characteristic
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Sanbo Brain Hospital
Glioma
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs ([18F]FET and [18F]FMISO) to see if the imaging results will help with the placement of catheters for…
- Trial name
- NCT07778979
- Testing
- [18F]FMISO-PET with contrast-enhanced MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing…
- Trial name
- NCT04552886
- Testing
- TH-1 Dendritic Cell Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- The Cooper Health System
Glioma, Malignant Glioma
FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
This is a pilot study designed to evaluate the potential of using FDOPA-PET/MRI for improving surgical planning and providing non-invasive prognostic information in patients with gliomas that have substantial non-enhancing…
- Trial name
- NCT02371031
- Testing
- 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine, PET/MRI, Surgical resection (standard of care)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Glioblastoma, Glioblastoma Multiforme
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize…
- Trial name
- NCT05281731
- Testing
- Sonobiopsy, Research blood, Cancer Personalized Profiling
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Anaplastic Glioma of Brain, Loss of Chromosomes 1p/19q
Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion
1. The management of anaplastic gliomas of WHO grade 3 is currently largely based on surgery followed by radiotherapy, of which prognosis remains still dismal with the median survival of 2-5 years.
- Trial name
- NCT01534845
- Testing
- Temozolomide (Temodal)
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Jong Hoon Kim
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
3T MRI Biomarkers of Glioma Treatment Response
This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01996527
- Testing
- 3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neoplasms
Continued Treatment for Participants Enrolled in Studies of BXQ-350
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the…
- Trial name
- ETERNITI (NCT04404569)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Brain and Central Nervous System Tumors, Thromboembolism
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas.
- Trial name
- NCT00253669
- Testing
- laboratory biomarker analysis, physiologic testing, management of therapy complications
- Where
- 9 sites in United States
- Volunteers
- 110 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma
Enhanced Detection in Glioma Excision
The purpose of this study is to determine whether use of an ultra-high sensitivity camera with enhanced imaging technology can be used during surgery to detect areas of brain tissue affected by diffuse glioma, a type of brain…
- Trial name
- EDGE (NCT04556929)
- Testing
- Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera, Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera, Biopsies
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Oxford
Recurrent or Refractory Pediatric Ependymoma
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.
- Trial name
- PETEY (NCT01032070)
- Testing
- erlotinib, etoposide
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 25 people
- Sponsor
- OSI Pharmaceuticals
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma, Gliomas
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Patients have a newly diagnosed brain tumor called a malignant glioma and participate in the study to see if it is possible to increase the benefit of temozolomide when given after radiation.
- Trial name
- NCT00200161
- Testing
- Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 127 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma
Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
This study evaluates how useful and acceptable the components of the "Couples Coping Together Against Cancer", referred to as "The Program", are to the participants with cancer.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT07664579
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Glioblastoma Multiforme
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
Clinical Part: The objective of this study is to determine the efficacy and safety of SUTENT in patients with recurrent or progressive glioblastoma multiforme.Patients with tissue based diagnosis of intracranial glioblastoma…
- Trial name
- SURGE01-07 (NCT00535379)
- Testing
- Sunitinib
- Where
- 10 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- Medical University Innsbruck
Solid Tumor, Glioblastoma
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma…
- Conditions
- Solid Tumor, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
- Trial name
- NCT05095441
- Testing
- C5252
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- ImmVira Pharma Co. Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.